Article Text

Download PDFPDF

5PSQ-031 Clinical and economic impact after breaking the single tablet abacavir/lamivudine/dolutegravir combo treatment into two drug regimens
  1. P Perez Puente,
  2. P Barriga Rodríguez,
  3. MR Garrido Ameigeiras,
  4. C Caba Hernández,
  5. P Tena Alejandre,
  6. JJ Duque Aguilar,
  7. J Sanchez Ferrer,
  8. S Arnaiz Diez,
  9. LC Fernández Lisón
  1. Complejo Hospitalario Universitario De Caceres, Hospital Pharmacy, Caceres, Spain


Background and importance In June 2018, our HIV regional working group, in a programme to improve the efficiency of antiretroviral therapy (ART), recommended changing from a single tablet regimen (STR) with abacavir/lamivudine/dolutegravir (ABC/3TC/DTG) once daily to abacavir/lamivudine (ABC/3TC) generic plus dolutegravir (DTG) once daily.

Aim and objectives To evaluate the degree of implementation of this strategy and the impact in terms of adherence and efficiency after 9 months.

Material and methods The retrospective descriptive study (June 2018–March 2019) included all HIV patients treated with STR ABC/3TC/DTG. To measure adherence, the consumption and dispensation registry of the pharmacy service software programme was used. Patients with a value >95% were considered adherent. The analytical variables collected were viral load (VL, copies/mL) and CD4 lymphocytes (cells/µL) (last available analytical before the change and at least 3 months later). Costs considered were hospital average prices according to the regional public tender.

Results Fifty-two patients, mean age 51.56 years, receiving treatment with ABC/3TC/DTG, were included. The change in ART was carried out in all patients.

Forty-four patients (84.6%) were adherent (>95%) before the switch and remained so after the change. We detected 8 (15.4%) patients with suboptimal adherence( <95%), with a mean adherence prior to the change of 81.5% (SD 5.3%) and after the change 84.3% (SD 6, 2%). Before the change, 49 patients (94.2%) presented undetectable VL, 2 patients (3.8%) had between 50 and 200 copies/mL and 1 patient (1.9%) had VL >200 copies/mL. After the change, 46 patients were evaluated (6 did not have analytics), 43 (93.4%) with undetectable VL, 2 (4.3%) with VL 50–200 copies/mL and 1 patient (2.1%) with VL >200 copies/mL.

The average level of LCD4 in the pre-change analysis was 808.67/µL (SD 205) and after the switch 785.4/µL (SD 308).

Cost savings were 132€/patient/month (1584€/patient/year). The estimated savings for the hospital since this efficiency measure was implemented until March 2019 was 41 000€.

Conclusion and relevance The results of the study, despite its limitations, demonstrated that after the switch, levels of virological suppression were maintained with a significant reduction in healthcare costs without affecting patient adherence to ART. More exhaustive and long term studies should be carried out to corroborate these results.

References and/or acknowledgements No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.